Tulobuterol hydrochloride

Synonyms: 盐酸妥布特罗; C-78
Tulobuterol hydrochloride (C-78) 是一种长效的 β2 肾上腺素受体 (β2-adrenoceptor) 激动剂,可减少慢性阻塞性肺疾病和支气管哮喘的发作频率,同时也是一种用作透皮贴剂的拟交感神经药,可增加正常的横膈膜肌肉力量,并能抑制鼻病毒 (rhinovirus) 复制、调节气道炎症。
产品编号: MS-J44135 纯度: 99.83% CAS No.: 56776-01-3 分子式: C12H19Cl2NO 分子量: 264.19
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
50mg
询价
3-5 天
100mg
询价
3-5 天
250mg
询价
3-5 天
500mg
询价
3-5 天
1g
询价
询价
5g
询价
询价

产品描述

Tulobuterol hydrochloride (C-78) 是一种长效的 β2 肾上腺素受体 (β2-adrenoceptor) 激动剂,可减少慢性阻塞性肺疾病和支气管哮喘的发作频率,同时也是一种用作透皮贴剂的拟交感神经药,可增加正常的横膈膜肌肉力量,并能抑制鼻病毒 (rhinovirus) 复制、调节气道炎症。

生物实验数据

生物活性 Tulobuterol hydrochloride (C-78) is a long-acting β2-adrenoceptor agonist that reduces the frequency of exacerbations of chronic obstructive pulmonary disease and bronchial asthma, and is also a sympathomimetic used as a transdermal patch that increases normal diaphragm muscle strength, while inhibiting rhinovirus replication and modulating airway inflammation.
IC50 & Target

β2-adrenoceptor

体外研究
(In Vitro)

Tulobuterol (0.1 μM; 24 hours or 72 hours; human tracheal epithelial cells) treatment decreases the RV14 RNA levels at 1 day and at 3 days after infection. The concentrations of sICAM-1 in the supernatants of the cells treated with tulobutero are significantly lower than those in the cells treated with vehicle before RV14 infection. Treatment with tulobuterol reduces the number of acidic endosomes with green fluorescence in the cells and the fluorescence intensity of acidic endosomes in the cells. Also reduces the RV14 infection-induced secretion of IL-1β, IL-6, and IL-8. Tulobuterol treatment produces a small but significant reduction in the amount of p50, p65, and c-Rel of NF-κB induced by RV14 infection.

RT-PCR

Cell Line: Human tracheal epithelial cells infected with RV14
Concentration: 0.1 μM
Incubation Time: 24 hours or 72 hours
Result: Decreased the RV14 RNA levels at 1 day and at 3 days after infection. The concentrations of sICAM-1 in the supernatants of the cells were significantly lower. Reduced the number of acidic endosomes with green fluorescence in the cells and the fluorescence intensity of acidic endosomes in the cells. Also reduced the RV14 infection-induced secretion of IL-1β, IL-6, and IL-8. And produced a small but significant reduction in the amount of p50, p65, and c-Rel of NF-κB induced by RV14 infection.
体内研究
(In Vivo)

In vivo effect of Tulobuterol is examined the on the contractility of diaphragm muscles prepared from mice (BALBs/c mice; 21.7 ± 0.2 g) treated with Endotoxin. Contractile parameters of force-frequency curves and twitch kinetics using untreated or treated diaphragm muscles at 0 (E0) and 4 (E4) hours after E. coli endotoxin (20 mg/kg) administration are measured. E0 and E4 diaphragm muscles are analyzed at 0, 12, and 24 h after transdermal Tulobuterol treatment. The force-frequency curves of E0 and E4 diaphragm muscles at three time points are not significantly changed each other, indicating that Tulobuterol patch restores the muscle contractility. Thus, diaphragm muscle contractility is maintained during 4 h of endotoxin administration with Tulobuterol patch for over 24 h.

性状 固体
颜色 White to off-white

化学信息

分子量 264.19
分子式 C12H19Cl2NO
CAS No. 56776-01-3
别名 盐酸妥布特罗; C-78

储存&溶解度

体内实验配方
10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (7.57 mM), Sonication is recommended.
请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。
储存方式

4°C, sealed storage, away from moisture

*In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

H2O 中的溶解度 : 100 mg/mL (378.52 mM; 超声助溶)

DMSO 中的溶解度 : 50 mg/mL (189.26 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO / H2O1 mM3.7852 mL18.9258 mL37.8515 mL94.6289 mL
5 mM0.7570 mL3.7852 mL7.5703 mL18.9258 mL
10 mM0.3785 mL1.8926 mL3.7852 mL9.4629 mL
15 mM0.2523 mL1.2617 mL2.5234 mL6.3086 mL
20 mM0.1893 mL0.9463 mL1.8926 mL4.7314 mL
25 mM0.1514 mL0.7570 mL1.5141 mL3.7852 mL
30 mM0.1262 mL0.6309 mL1.2617 mL3.1543 mL
40 mM0.0946 mL0.4731 mL0.9463 mL2.3657 mL
50 mM0.0757 mL0.3785 mL0.7570 mL1.8926 mL
60 mM0.0631 mL0.3154 mL0.6309 mL1.5771 mL
80 mM0.0473 mL0.2366 mL0.4731 mL1.1829 mL
100 mM0.0379 mL0.1893 mL0.3785 mL0.9463 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础